Pubblicazioni significative
- Myers SH, Poppi L, Rinaldi F, Veronesi M, Ciamarone A, Previtali V, Bagnolini G, Schipani F, Ortega Martínez JA, Girotto S, Di Stefano G, Farabegoli F, Walsh N, De Franco F, Roberti M, Cavalli A. (2024). An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer. Eur J Med Chem. Vol. 265, Article number 116114, doi: 10.1016/j.ejmech.2023.116114
- Bagnolini,G., Balboni, B., Schipani, F., Gioia ,D., Veronesi , M., De Franco , F,. Kaya , C., Jumde , R.P., Ortega ,J.A., Girotto , S., Hirsch , A.K.H., Roberti , M., Cavalli, A. (2022). Identification of RAD51-BRCA2 Inhibitors Using N-Acylhydrazone-Based Dynamic Combinatorial Chemistry. ACS Med Chem Lett. Vol. 13, 1262-1269, doi: 10.1021/acsmedchemlett.2c00063
- Mazzei, L., Contaldo, U., Musiani, F., Cianci, M., Bagnolini, G., Roberti, M., Stefano Ciurli, S. (2021).Inhibition of urease, a Ni-enzyme: the reactivity of a key thiol with mono- and di-substituted catechols elucidated by kinetic, structural and theoretical studies. ANGEW CHEM INT ED ENGL. vol. 60, p. 6029-6035, doi: 10.1002/anie.202014706
- Bagnolini G., Milano D., Manerba M., Schipani F., Ortega J. A., Gioia D., Falchi F., Balboni A., Farabegoli F., De Franco F., Robertson J., Pellicciari R., Pallavicini I., Peri S., Minucci S., Girotto S., Di Stefano G., Roberti M., Cavalli A. (2020). Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib. JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, p. 2588-2619, doi: 10.1021/acs.jmedchem.9b01526
- Roberti, M., Schipani, F., Bagnolini, G., Milano, D., Giacomini, E., Falchi, F., Balboni, A., Manerba, M., Farabegoli, F., De Franco, F., Robertson, J., Minucci, S., Pallavicini, I., Di Stefano, G., Girotto, S., Pellicciari, R., and Cavalli, A. (2019). Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 165, p. 80-92, doi: 10.1016/j.ejmech.2019.01.008